|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM024165530 |
| 003 |
DE-627 |
| 005 |
20250125185320.0 |
| 007 |
tu |
| 008 |
231221s1986 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0081.xml
|
| 035 |
|
|
|a (DE-627)NLM024165530
|
| 035 |
|
|
|a (NLM)2435128
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Fujii, A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of stage D prostate cancer patients with hormones in combination with cyclophosphamide
|
| 264 |
|
1 |
|c 1986
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.04.1987
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Eleven patients with newly diagnosed stage D prostate cancer between June, 1984 and June, 1985, were administered 300 mg/day of Honvan in 3 divided portions, 4 capsules/day of Estracyt in 2 divided portions, or 100 mg/day of Prostal in 2 divided portions was administered orally, concomitantly with large-dose intermittent treatment of 1 g/m2/3 weeks of cyclophosphamide. According to the NPCP criteria, of the 5 cases given Honvan 1 case was PR and 4 cases were stable: all 3 cases given Estracyt were stable: and in 3 cases given Prostal, 1 case was stable, 1 case had progression and 1 case dropped out. The response duration of this combination therapy was 3 to 16 months (average: 9.9 months), and obvious improvements in the subjective symptoms and performance status were noted in the cases that responded to the treatment. As for side effects, gastrointestinal symptoms were observed in 9 cases, leucopenia in 3 cases, and thrombocytopenia in 1 case. All these cases, however, were slight and transient. In 1 case, jaundice and an elevation in GOT and GPT were detected, but these changes were also temporary
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Hormones
|2 NLM
|
| 650 |
|
7 |
|a Chlormadinone Acetate
|2 NLM
|
| 650 |
|
7 |
|a 0SY050L61N
|2 NLM
|
| 650 |
|
7 |
|a Estramustine
|2 NLM
|
| 650 |
|
7 |
|a 35LT29625A
|2 NLM
|
| 650 |
|
7 |
|a Diethylstilbestrol
|2 NLM
|
| 650 |
|
7 |
|a 731DCA35BT
|2 NLM
|
| 650 |
|
7 |
|a Cyclophosphamide
|2 NLM
|
| 650 |
|
7 |
|a 8N3DW7272P
|2 NLM
|
| 700 |
1 |
|
|a Yasuno, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kawaida, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakamura, I
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 32(1986), 11 vom: 30. Nov., Seite 1713-7
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnas
|
| 773 |
1 |
8 |
|g volume:32
|g year:1986
|g number:11
|g day:30
|g month:11
|g pages:1713-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 1986
|e 11
|b 30
|c 11
|h 1713-7
|